Zebrafish as a model organism for the identification and characterization of drugs and genes affecting p53 signaling

Current Biology

Volumn 12, Issue 23, 2002, Pages 2023-2028

  Langheinrich, Ulrike ^a   Hennen, Elisabeth ^a   Stott, Gordon ^a   Vacun, Gabi ^a  

^a Exelixis Deutschland GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; MESSENGER RNA; POLYADENYLIC ACID; PROTEIN MDM2; PROTEIN P53; TRANSCRIPTION FACTOR; MDM2 PROTEIN, ZEBRAFISH; NUCLEAR PROTEIN; ONCOPROTEIN; ZEBRAFISH PROTEIN;

ANIMAL MODEL; APOPTOSIS; CANCER THERAPY; DRUG DEVELOPMENT; DRUG IDENTIFICATION; KNOCKOUT GENE; SIGNAL TRANSDUCTION; ANIMAL; ANIMAL EMBRYO; ARTICLE; CELL CYCLE; CYTOLOGY; GENE DELETION; GENETICS; MAMMAL; MORPHOGENESIS; NEOPLASM; PHYSIOLOGY; PRENATAL DEVELOPMENT; TUMOR SUPPRESSOR GENE; ZEBRA FISH;

DANIO RERIO;

ANIMALS; APOPTOSIS; CELL CYCLE; EMBRYO, NONMAMMALIAN; GENE DELETION; GENES, P53; MAMMALS; MODELS, ANIMAL; MORPHOGENESIS; NEOPLASMS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; ZEBRAFISH; ZEBRAFISH PROTEINS;

EID: 0036898541     PISSN: 09609822     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9822(02)01319-2     Document Type: Article

References (24)

1. Lane, D.P. (1992). Cancer. p53, guardian of the genome. Nature 358, 15-16.
2. Bates, S., and Vousden, K.H. (1996). p53 in signaling checkpoint arrest or apoptosis. Curr. Opin. Genet. Dev. 6, 12-18.
3. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C.C. (1991). p53 mutations in human cancers. Science 253, 49-53.
4. Tishler, R.B., Calderwood, S.K., Coleman, C.N., and Price, B.D. (1993). Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents. Cancer. Res. Suppl. 53, 2212-2216.
5. Zhang, Z.W., Patchett, S.E., and Farthing, M.J. (2000). Topoisomerase I inhibitor (camptothecin)-induced apoptosis in human gastric cancer cells and the role of wild-type p53 in the enhancement of its cytotoxicity. Anticancer Drugs 11, 757-764.
6. O'Connor, P.M., Jackman, J., Bae, I., Myers, T.G., Fan, S., Mutoh, M., Scudiero, D.A., Monks, A., Sausville, E.A., Weinstein, J.N., et al. (1997). Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 57, 4285-4300.
7. Lu, X., and Lane, D.P. (1993). Differential induction of transcriptionally active p53 following UV or ionizing radiation: Defects in chromosome instability syndromes? Cell 75, 765-778.
8. Lu, W., Chen, L., Peng, Y., and Chen, J. (2001). Activation of p53 by roscovitine-mediated suppression of MDM2 expression. Oncogene 20, 3206-3216.
9. Donehower, L.A., Harvey, M., Slagle, B.L., McArthur, M.J., Montgomery, C.A., Jr., Butel, J.S., and Bradley, A. (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 215-221.
10. Alarcon-Vargas, D., and Ronai, Z. (2002). p53-Mdm2 - the affair that never ends. Carcinogenesis 23, 541-547.
11. Haupt, Y., Maya, R., Kazaz, A., and Oren, M. (1997). Mdm2 promotes the rapid degradation of p53. Nature 387, 296-299.
12. Montes de Oca Luna, R., Wagner, D.S., and Lozano, G. (1995). Rescue of early embryonic lethality in Mdm2-deficient mice by deletion of p53. Nature 378, 203-205.
13. Jones, S.N., Roe, A.E., Donehower, L.A., and Bradley, A. (1995). Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378, 206-208.
14. Parant, J., Chaves-Reyes, A., Little, N.A., Yan, W., Reinke, V., Jochemsen, A.G., and Lozano, G. (2001). Rescue of embryonic lethality in MDM4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat. Genet. 29, 92-95.
15. Chen, L., Lu, W., Agrawal, S., Zhou, W., Zhang, R., and Chen, J. (1999). Ubiquitous induction of p53 in tumor cells by antisense inhibition of MDM2 expression. Mol. Med. 5, 21-34.
16. Cheng, R., Ford, B.L., O'Neal, P.E., Mathews, C.Z., Bradford, C.S., Thongtan, T., Barnes, D.W., Hendricks, J.D., and Bailey, G.S. (1997). Zebrafish (Danio rerio) p53 tumor suppressor gene: cDNA sequence and expression during embryogenesis. Mol. Mar. Biol. Biotechnol. 6, 88-97.
17. Thisse, C., Neel, H., Thisse, B., Daujat, S., and Piette, J. (2000). The MDM2 gene of zebrafish (Danio rerio): Preferential expression during development of neural and muscular tissues, and absence of tumor formation affer overexpression of its cDNA during early embryogenesis. Differentiation 66, 61-70.
18. Li, L., Liao, J., Ruland, J., Mak, T.W., and Cohen, S.N. (2001). A TSG101/MDM2 regulatory loop modulates MDM2 degradation and MDM2/p53 feedback control. Proc. Natl. Acad. Sci. USA 98, 1619-1624.
19. Ruland, J., Sirard, C., Elia, A., MacPherson, D., Wakeham, A., Li, L., de la Pompa, J.L., Cohen, S.N., and Mak, T.W. (2001). p53 accumulation, defective cell proliferation, and early embryonic lethality in mice lacking Tsg101. Proc. Natl. Acad. Sci. USA 98, 1859-1864.
20. Sun, X., Shimizu, H., and Yamamoto, K. (1995). Identification of a novel p53 promoter element involved in genotoxic stress-inducible p53 gene expression. Mol. Cell. Biol. 15, 4489-4496.
21. Laverdiere, M., Beaudoin, J., and Lavigueur, A. (2000). Species-specific regulation of alternative splicing in the C-terminal region of the p53 tumor suppressor gene. Nucleic Acids Res. 28, 1489-1497.
22. Han, K.A., and Kilesz-Martin, M.F. (1992). Alternatively spliced p53 RNA in transformed and normal cells of different tissue types. Nucleic Acids Res. 25, 1979-1981.
23. Jaks, V., Joers, A., Kristjuhan, A., and Maimets, T. (2001). p53 protein accumulation in addition to the transactivation activity is required for p53-dependent cell cycle arrest after treatment of cells with camptothecin. Oncogene 20, 1212-1219.
24. Ball, K.L. (1997). p21: Structure and functions associated with cyclin-CDK binding. Prog. Cell Cycle Res. 3, 125-134.